Story perspectives

FDA Panel Adds Six Peptides to Compounding List Amid Controversy

7/28/2026

Summary

FDA Adds Peptides

July 23-24, 2026, the FDA Pharmacy Compounding Advisory Committee voted to add peptides—BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax—to the 503A list.
Eight members appointed by Health Secretary Robert F. Kennedy Jr., some with industry ties, voted 7-4 to 8-6 in favor and 6-7 against emideltide (DSIP).
FDA scientists opposed seven peptides, citing limited data, safety and contamination risks, making the recommendation nonbinding pending rulemaking that may take months to years.

Summary

Rogan Promotes Peptides

Health Secretary Robert F. Kennedy Jr. called himself a “big fan” of peptides and removed several from the FDA’s high-risk list earlier this year.
The unregulated peptide market is valued between $100 million and $3 billion in the United States and United Kingdom.
Influencer Joe Rogan promoted BPC-157 and TB-500, raising their popularity despite no FDA approval.
Experts say dosing regimens for the new peptides are undefined, leaving consumers to experiment without medical guidance.

History

Historical Context

Senators Orrin Hatch and Tom Harkin pushed the Dietary Supplement Health and Education Act, which President Bill Clinton signed on Oct 25 1994, classifying supplements as foods and eliminating pre-market safety review. The resulting $5 billion-a-year loophole now underlies Health Secretary Robert F. Kennedy Jr.’s addition of peptide ingredients to the FDA’s 503A list, a move backed by Joe Rogan and tied to a market valued around $100 million-$3 billion.

1 of 3

FDA Adds Peptides

July 23-24, 2026, the FDA Pharmacy Compounding Advisory Committee voted to add peptides—BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax—to the 503A list.
Eight members appointed by Health Secretary Robert F. Kennedy Jr., some with industry ties, voted 7-4 to 8-6 in favor and 6-7 against emideltide (DSIP).
FDA scientists opposed seven peptides, citing limited data, safety and contamination risks, making the recommendation nonbinding pending rulemaking that may take months to years.

1 / 3